Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur ROGER GUILLEMINOT-LARUELLE

RPPS 10004599949

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer

    British journal of pharmacology · 2026

    📚 12 citations🎯 RCR 12.00🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Background and Purpose Triple‐negative breast cancer (TNBC) has poorer outcomes than other breast cancers (BC), including HER2 + BC. Cathepsin D (CathD) is a poor prognosis marker overproduced by BC cells, hypersecreted in the tumour microenvironment with tumour‐promoting activity. Here, we characterized the immunomodulatory activity of the anti‐CathD antibody F1 and its improved Fab‐aglycosylated version (F1M1) in immunocompetent mouse models of TNBC (C57BL/6 mice harbouring E0771 cell grafts) and HER2‐amplified BC (BALB/c mice harbouring TUBO cell grafts). Experimental Approach CathD expression was evaluated by western blotting and immunofluorescence, and antibody binding to CathD by ELISA. Antibody anti‐tumour efficacy was investigated in mouse models. Immune cell recruitment and activation were assessed by immunohistochemistry, immunophenotyping, and RT‐qPCR. Key Results F1 and F1M1 antibodies remodelled the tumour immune landscape. Both antibodies promoted innate antitumour immunity by preventing the recruitment of immunosuppressive M2‐polarized tumour‐associated macrophages (TAMs) and by activating natural killer cells in the tumour microenvironment of both models. This translated into a reduction of T‐cell exhaustion markers in the tumour microenvironment that could be locally supported by enhanced activation of anti‐tumour antigen‐presenting cell (M1‐polarized TAMs and cDC1 cells) functions. Both antibodies inhibited tumour growth in the highly‐immunogenic E0771 model, but only marginally in the immune‐excluded TUBO model, indicating that anti‐CathD immunotherapy is more relevant for BC with a high immune cell infiltrate, as often observed in TNBC. Conclusion and implication Anti‐CathD antibody‐based therapy triggers the anti‐tumour innate and adaptive immunity in preclinical models of BC and is a promising immunotherapy for immunogenic TNBC. LINKED ARTICLES This article is part of a themed issue Immunotherapy in Cancer. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.6/issuetoc

  • 2
    ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation

    Kidney international reports · 2026

    📚 1 citations🔓 Open Access

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal33

Case report / série3

Essai clinique3

Épidémiologie & registres2

Pharmacovigilance2

Gériatrie1

IA en rhumatologie1

Qualité de vie / PROMs1

Revue générale1

Risque cardio-vasculaire1

Santé mentale / fatigue1

Vascularites des gros vaisseaux1

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.